Dupilumab Improves Atopic Dermatitis and Post-Inflammatory Hyperpigmentation in Patient With Skin of Color.

Atopic dermatitis, a chronic inflammatory condition, accounts for numerous dermatology visits for patients with skin of color. The inflammatory process often leads to post-inflammatory hyperpigmentation, especially in patients with skin of color, which may negatively impact quality of life. We present a case that demonstrates clinical improvement of atopic dermatitis, post inflammatory hyperpigmentation, and lightening of pigmentation in clinically non-lesional areas after initiation of dupilumab. Lightening of the patient's skin even in areas that previously appeared clinically normal supports the scientific evidence that non-lesional skin in those with atopic dermatitis is often subclinically involved. For skin of color patients, aggressive treatment with duplimab may accelerate the return of the patient's overall normal skin tone. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.4937.